Phase 1 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting (NCT06701721)

Phase 1 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting NCT06701721 Sponsor: Therini Bio Pty Ltd Condition: Retinal Vein Occlusion and Diabetic Macular Oedema

Printed from Voxsanity (voxsanity.com.au) — NCT06701721 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Retinal Vein Occlusion

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are willing and able to understand the study procedures and risks, and can provide written consent before any study-related activities begin
People aged 18 to 80 years old (inclusive) at the time of giving consent
People who have been diagnosed with Diabetic Macular Edema (DME), a condition where fluid builds up in the central part of the retina due to diabetes
People who have experienced vision loss in the eye being studied

Who may not be able to join:

People who are pregnant or breastfeeding
People who have had cataract surgery or any other eye surgery on the study eye within the 3 months before the screening visit
People who have any other eye or health condition, aside from DME, that could affect how the study results are interpreted (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Joel Naor, Therini Bio, Inc.

Phone: +1 (925) 819-1952

Australian sites

Marsden Eye Specialists, Parramatta, New South Wales
+ 61 2 9635 7077

South Eastern Sydney Local Health District, Sydney, New South Wales
+61 02 9382 7309

Sydney West Retina, Westmead, New South Wales
+61 2 9893 9022

Princess Alexandria Hospital, Woolloongabba, Queensland
+61 7 3443 8050

Royal Adelaide Hospital, Adelaide, South Australia
+61 08 7074 2257

Sunshine Eye Surgeons, Albans, Victoria
+61 3 9077 3235

Eye Surgery Associates Pty Ltd, Malvern, Victoria
+61 402 133 315

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06701721

Sponsor: Therini Bio Pty Ltd

Phase: Phase 1

Status: Recruiting

Condition: Retinal Vein Occlusion and Diabetic Macular Oedema

Trial contact: +1 (925) 819-1952

More information: https://clinicaltrials.gov/study/NCT06701721

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are willing and able to understand the study procedures and risks, and can provide written consent before any study-related activities begin
People aged 18 to 80 years old (inclusive) at the time of giving consent
People who have been diagnosed with Diabetic Macular Edema (DME), a condition where fluid builds up in the central part of the retina due to diabetes
People who have experienced vision loss in the eye being studied

Who may not be able to join:

People who are pregnant or breastfeeding
People who have had cataract surgery or any other eye surgery on the study eye within the 3 months before the screening visit
People who have any other eye or health condition, aside from DME, that could affect how the study results are interpreted (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Therini Bio Pty Ltd

Registry

ClinicalTrials.gov

Start date

20 December 2024

Est. completion

31 March 2027

Where this trial is recruiting

🇦🇺 Australia

7 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov